NKGen Biotech, Inc. Common Stock (NKGN PINK) stock market data APIs
$0.1563
-0(-0%)
as of March 27, 2025
NKGen Biotech, Inc. Common Stock Financial Data Overview
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
Prev. Close
0.1612
Open
0.1563
High
0.1986
Low
0.1523
52 wk Range
0.12-2.19
Market Cap
7 281 K
Shares Outstanding
45 281 K
EPS
0.1526
Beta
0.446
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NKGen Biotech, Inc. Common Stock data using free add-ons & libraries
Get NKGen Biotech, Inc. Common Stock Fundamental Data
NKGen Biotech, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -30 112 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-09-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NKGen Biotech, Inc. Common Stock News
New
NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented
Trading commencing on the OTC Markets on March 5, 2025.Trading expected to continue under ticker symbol “NKGN” for common stock and “NKGNW” for warrants.NKGen Biotech, Inc. (“NKGen” or the...
NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program
SANTA ANA, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and comm...
NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer’s Disease with AdventHealth Orlando as First East Coast Site
SANTA ANA, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and comm...
NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
NKGen Biotech SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the develop...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
